Clinical Trials | April 22, 2026
Asahi Kasei pushes into human trials with new autoimmune drug candidate
The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp
The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp
Originally established in Punjab, the Vasculitis Society of India is now expanding its footprint nationwide
The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options
Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology
Asahi Kasei Pharma receives worldwide exclusive rights for the research, development, manufacturing, and marketing of the active ingredients
Asahi Kasei is consistently pursuing its strategy of building a focused, sustainable specialty pharmaceutical platform for immunocompromised and medically complex patient groups
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
The acquisition brings Lilly a novel in vivo cell therapy platform built around engineered circular RNA and proprietary lipid nanoparticles
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
